- CRB-913 is a novel oral cannabinoid type 1 receptor (CB1)
inverse agonist with potent pre-clinical anti-obesity
activity
- CRB-913 markedly enhances pre-clinical efficacy of
liraglutide, semaglutide, and tirzepatide
- CB1 inverse agonism is a clinically validated therapeutic
approach to treating obesity
NORWOOD,
Mass., Sept. 22, 2022 /PRNewswire/ -- Corbus
Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the
"Company"), an immunology company, announced that preclinical data
for CRB-913 are being presented today in an oral presentation at
the European Association for the Study of Diabetes 2022 Annual
Conference taking place in Stockholm, Sweden.
The data show that in the diet-induced obesity (DIO) mouse
model, CRB-913 monotherapy demonstrated a reduction in body weight,
body fat content, food consumption, liver triglycerides, and liver
fat deposits as well as improvements in insulin resistance and
leptinemia. Combining CRB-913 with the incretin analogues
liraglutide, semaglutide, or tirzepatide demonstrated significant
additive effects across all these outcomes.
"The data presented today are exciting as they demonstrate that
CRB-913 is a differentiated CB1 inverse agonist with improved
pharmacokinetic properties compared to the first generation of
these drugs while still retaining the same efficacy," commented
Rachael Brake, Ph.D., Chief
Scientific Officer of Corbus. "Furthermore, potentially combining
CRB-913 with an incretin analogue into a single therapy could
meaningfully enhance the current standard of care as well as expand
the number of patients who could benefit from anti-obesity drug
therapy."
The EASD presentation is available on the company's website at:
58th European Association for the Study of Diabetes
(EASD) presentation on CRB-913 (CB1 Inverse Agonist).
About Corbus
Corbus is an immunology company committed to helping people
defeat serious illness by bringing innovative scientific approaches
to well understood biological pathways. Corbus' current pipeline
includes anti-integrin monoclonal antibodies that block activation
of TGFβ and small molecules that activate or inhibit the
endocannabinoid system. Corbus is headquartered in Norwood, Massachusetts. For more information
on Corbus, visit corbuspharma.com and connect on Twitter, LinkedIn,
and Facebook.
Forward-Looking
Statements
This press release contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 and Private
Securities Litigation Reform Act, as amended, including those
relating to the Company's restructuring, trial results, product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statement that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of forward-looking
expressions, including, but not limited to, "expect," "anticipate,"
"intend," "plan," "believe," "estimate," "potential," "predict,"
"project," "should," "would" and similar expressions and the
negatives of those terms. These statements relate to future events
or our financial performance and involve known and unknown risks,
uncertainties, and other factors, including the potential impact of
the recent COVID-19 pandemic and the potential impact of sustained
social distancing efforts, on our operations, clinical development
plans and timelines, which may cause actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Such factors include those set forth in
the Company's filings with the Securities and Exchange Commission.
Prospective investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of
this press release. The Company undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise.
INVESTOR CONTACT:
Corbus Investor Relations
Sean.moran@corbuspharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/corbus-presents-first-pre-clinical-data-for-crb-913-at-the-european-association-for-the-study-of-diabetes-2022-annual-conference-301630440.html
SOURCE Corbus Pharmaceuticals